Patients undergoing allogeneic HSCT for correction of a primary immunodeficiency disorder (e.g. severe combined immunodeficiency [SCID])
Any form of primary immunodeficiency (such as severe combined immunodeficiency disease and acquired immunodeficiency syndrome [AIDS])
Any form of primary immunodeficiency (such as severe combined immunodeficiency disease)
Any form of primary immunodeficiency (such as severe combined immunodeficiency disease)
Any form of primary immunodeficiency (such as severe combined immunodeficiency disease and acquired immune deficiency syndrome [AIDS])
Any form of primary immunodeficiency (such as severe combined immunodeficiency disease).
Any form of primary immunodeficiency (such as severe combined immunodeficiency disease)
Any form of primary immunodeficiency (such as severe combined immunodeficiency disease and acquired immunodeficiency syndrome [AIDS])
Any form of primary immunodeficiency (such as severe combined immunodeficiency disease)
Any form of primary immunodeficiency.
Any form of systemic immunodeficiency, including acquired deficiency such as HIV or primary immunodeficiency such as severe combined immunodeficiency disease
Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease)
Any form of primary immunodeficiency (such as severe combined immunodeficiency disease)
Any form of primary immunodeficiency (such as severe combined immunodeficiency disease)
Any form of primary immunodeficiency (such as severe combined immunodeficiency disease)
Any form of primary immunodeficiency (such as severe combined immunodeficiency disease)
Any form of primary immunodeficiency (such as severe combined immunodeficiency disease)
Any form of primary immunodeficiency (such as severe combined immunodeficiency disease)
Any form of primary immunodeficiency (such as severe combined immunodeficiency disease)
Any form of primary immunodeficiency (such as severe combined immunodeficiency disease)
Any form of primary immunodeficiency (such as severe combined immunodeficiency disease)
Any form of primary immunodeficiency (such as severe combined immunodeficiency disease)
Any form of primary immunodeficiency (such as severe combined immunodeficiency disease)
Any form of primary immunodeficiency (such as severe combined immunodeficiency disease)
Any form of primary immunodeficiency (such as severe combined immunodeficiency disease)
Any form of primary immunodeficiency (such as severe combined immunodeficiency disease)
Any form of primary immunodeficiency (such as severe combined immunodeficiency disease)
Any form of primary immunodeficiency (such as severe combined immunodeficiency disease)
Any form of primary immunodeficiency (such as severe combined immunodeficiency disease)
Any form of primary immunodeficiency (such as severe combined immunodeficiency disease)
Any form of primary immunodeficiency (such as severe combined immunodeficiency disease)
Any form of primary immunodeficiency (such as severe combined immunodeficiency disease)
Any form of primary immunodeficiency (such as severe combined immunodeficiency disease and acquired immune deficiency syndrome [AIDS])
Any form of primary immunodeficiency (such as severe combined immunodeficiency disease)
Any form of primary immunodeficiency (such as severe combined immunodeficiency disease)
Patients known to be human immunodeficiency virus (HIV) positive with a baseline cluster of differentiation (CD)4 count of < 250 cells/mm^3 or have a history of acquired immune deficiency syndrome (AIDS) indicator conditions
STEP I: Human immunodeficiency virus (HIV) infection is not excluded; known HIV positive patients must meet the following criteria:\r\n* Cluster of differentiation (CD)4 cell count >= 350/mm^3\r\n* No history of acquired immune deficiency syndrome (AIDS)-related illness\r\n* Not currently prescribed zidovudine or stavudine
Patients known to be human immunodeficiency virus (HIV) positive with one or more of the following:\r\n* Baseline cluster of differentiation (CD)4 count of < 250 cells/mm^3\r\n* History of acquired immune deficiency syndrome (AIDS) indicator conditions\r\n* Anti-retroviral therapy with any potent CYP3A4 inhibitor
Participants with persistently low CD4 counts less than 200 and a history of any acquired immune deficiency syndrome (AIDS)-defining infection in the last 6 months before screening are excluded from the study
Any patient with a history of genetic or acquired immune suppression disease such as human immunodeficiency virus (HIV) is excluded; subjects on immune suppressive therapy for organ transplant are also excluded
Active, known, or suspected immunosuppressive disorders, such as acquired or congenital immune deficiency syndromes and autoimmune diseases
Active uncontrolled infection, including known history of human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) or hepatitis B or C
Known infection with human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS) (testing not required).
History or current status of immune system abnormalities such as hyperimmunity (e.g., autoimmune diseases) that needed to be treated by systemic therapy, such as immuno-suppressants and hypoimmunity (e.g., myelodysplatic disorders, marrow failures, acquired immune deficiency syndrome [AIDS], transplant immunosuppression)
Acquired immune deficiency syndrome (AIDS) due to the potential for increased complications from treatment; note, however, that HIV testing is not required
Have known immune system disorders (including acquired immunodeficiency syndrome [AIDS], HIV infection or hepatitis B or C); eligible patients must have a negative HIV test result within 4 weeks prior to study initiation
History or current status of immune system abnormalities such as hyperimmunity (e.g., autoimmune diseases) that needed to be treated by systemic therapy, such as immuno-suppressants and hypoimmunity (e.g., myelodysplastic disorders, marrow failures, acquired immune deficiency syndrome [AIDS], transplant immunosuppression)
Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; protocol-specific requirements may also exclude immune-compromised patients
Known to have lymphoma related to HIV or acquired immune deficiency syndrome (AIDS)
EXCLUSION - TREATMENT: Known primary immune deficiency or HIV positivity
Patients with human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) and those severely immunocompromised will be excluded; however, no patients will be tested for HIV
Presence of any condition or concurrent requirement for treatment with agents known to result in immune deficiency.
Human immunodeficiency virus (HIV) seropositivity or other congenital or acquired immune deficiency state, which would increase the risk of opportunistic infections and other complications during chemotherapy-induced lymphodepletion; if there is a positive result in the infectious disease testing that was not previously known, the patient will be referred to their primary physician and/or infectious disease specialist
Patients with known congenital or acquired immune deficiency (including those patients who require systemic immunosuppressant drugs for autoimmune disease or organ transplant)
Known Human Immunodeficiency Virus (HIV) or Acquired Immune Deficiency Syndrome (AIDS)
Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; the need to exclude patients with AIDS from this protocol is necessary
Human immunodeficiency virus (HIV) seropositivity or other congenital or acquired immune deficiency state, which would increase the risk of opportunistic infections and other complications during chemotherapy-induced lymphodepletion; if there is a positive result in the infectious disease testing that was not previously known, the patient will be referred to their primary physician and/or infectious disease specialist
Known history of human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS)
Active or history of uveal, mucosal, or ocular melanoma. Human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS)-related illness, chronic hepatitis B or C.
History of any chronic Hepatitis, active Hepatitis B or C, human immunodeficiency virus (HIV), or acquired immune deficiency syndrome (AIDS)
Acquired immune deficiency syndrome (AIDS) based upon current Center for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol
Has known immunosuppressive disease (e.g. human immunodeficiency virus [HIV], acquired immune deficiency syndrome [AIDS] or other immune depressing disease); testing is not mandatory
Human immunodeficiency virus (HIV) seropositivity or other congenital or acquired immune deficiency state; if there is a positive result in the infectious disease testing that was not previously known, the patient will be referred to their primary physician and/or infectious disease specialist
Subjects who require human immunodeficiency virus (HIV) protease inhibitors or those with acquired immune deficiency syndrome (AIDS)-related illness
Known human immunodeficiency virus (HIV) positivity or acquired immune deficiency syndrome (AIDS)-related illness
Immune deficiency: clinically significant primary or acquired immune deficiency (i.e. acquired immunodeficiency syndrome [AIDS] or on immunosuppressive medication after organ transplant)
Known human immunodeficiency virus positive (HIV[+]) or has been diagnosed with acquired immune deficiency syndrome (AIDS)
Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease and Control (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; protocol-specific requirements may also exclude immuno-compromised patients
Active uncontrolled infection, including known history of acquired immune deficiency syndrome (AIDS) or hepatitis B or C
Immuosuppressive disorders (chronic steroid therapy, acquired or congenital immune deficiency syndromes, autoimmune disease)
Patients with a known immune deficiency
Human immunodeficiency virus (HIV) seropositivity or other congenital or acquired immune deficiency state, which would increase the risk of opportunistic infections and other complications during chemotherapy-induced lymphodepletion; if there is a positive result in the infectious disease testing that was not previously known, the patient will be referred to their primary physician and/or infectious disease specialist
If there is clinical suspicion of acquired immune deficiency syndrome (AIDS), a human immunodeficiency virus (HIV) test must be done within 42 days prior to registration; Note: HIV positive patients with a cluster of differentiation (CD)4+ T cell count > 200 per uL of blood and > 14% of all lymphocytes are eligible for this trial
Patients with immune deficiency have impaired immune responses, therefore, known human immunodeficiency virus (HIV)-positive patients are excluded from the study
Patients with known history of human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS)
Evidence of immune suppression due to: a) known human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS); b) known leukemia or lymphoma; c) those who require high dose steroids (> 10 mg/day of prednisone or equivalent within 7 days prior to enrollment) or other immunosuppressive therapies (> 2 weeks); d) active hepatitis B or C; e) congenital or acquired cellular and/or humoral immune deficiency; f) other signs or symptoms of immune system suppression or concurrent opportunistic infection
Known positive testing for human immunodeficiency virus (HIV)or history of acquired immune deficiency syndrome (AIDS).
History of active primary immunodeficiency including, but not limited to acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; Note: human immunodeficiency virus (HIV) testing is not required for entry into this protocol; the need to exclude patients with AIDS from this protocol is necessary because the treatment involved in this protocol may be immunosuppressive; patients with known HIV, CD4 counts >= 200/uL, and undetectable viral loads who are stable on an antiretroviral regimen may be included
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; however, HIV-positive patients without an acquired immune deficiency syndrome (AIDS)-defining diagnosis who are not receiving agents with the potential for pharmacokinetic (PK) interactions with ABT-888 may be eligible
The first six patients enrolled in the Flt3L arm of the study cannot be human immunodeficiency virus (HIV)-positive; after the evaluation of safety in the first 6 patients, HIV-positive patients with adequate immune function as evidenced by stable cluster of differentiation (CD)4 counts >= 350/mm^3 are allowed to participate if the following criteria are met:\r\n* Maintained on stable antiretroviral therapy with no significant drug interactions, and \r\n* No recent history of acquired immune deficiency syndrome (AIDS) indicator conditions (> 2 years from enrolling in trial), and \r\n* Physician providing patient’s care for HIV must also approve of patient entering the study
Patients known to be human immunodeficiency virus (HIV) positive with a baseline cluster of differentiation (CD)4 count of < 250 cells/mm^3 or have a history of acquired immune deficiency syndrome (AIDS) indicator conditions; patients taking anti-retroviral therapy that may have a potential overlapping toxicity with the study therapy are not eligible
Human immunodeficiency virus (HIV) positive serology or acquired immune deficiency syndrome
Patients with immune deficiency are excluded
A known diagnosis of human immunodeficiency virus (HIV) infection or acquired immune\n             deficiency syndrome (AIDS), acute or chronic hepatitis B or hepatitis C infection, as\n             determined by medical history.
Human immunodeficiency virus (HIV) infection is not excluded; HIV+ patients must meet the following criteria:\r\n* Cluster of differentiation (CD)4 cell count >= 350/mm^3\r\n* No history of acquired immune deficiency syndrome (AIDS)-related illness\r\n* Not currently prescribed zidovudine or stavudine
Patients must not have any known immune deficiencies; patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy; therefore, known human immunodeficiency virus (HIV) positive patients receiving combination anti-retroviral therapy are excluded from the study
Evidence of clinically significant immunosuppression such as organ or stem cell transplantation, any severe congenital or acquired cellular and/or humoral immune deficiency, concurrent opportunistic infection.
Absence of history of acquired immune deficiency syndrome (AIDS)-related conditions (other than the presenting DLBCL) or post-transplant lymphoproliferative disorder (PTLD) in immunocompromised patients; patients with human immunodeficiency virus (HIV) on antiretroviral therapy other than zidovudine (AZT) and/or stavudine and without prior AIDS defining conditions and adequate CD4 count (> 400) are eligible
HIV positive patients with advanced immune suppression and evidence of HIV resistant to all combinations of antiretroviral therapy considered at high risk of non-lymphoma related death within 12-months due to other acquired immune deficiency syndrome (AIDS) complications should not be enrolled on the study
Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; patients with known AIDS will be ineligible for this protocol; patients with clinical suspicion of AIDS and who are unwilling to have an HIV test are not eligible for this trial
Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition
Evidence of immune suppression due to: \r\n* Known human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)\r\n* Known leukemia or lymphoma\r\n* Those who require high dose steroids or other immunosuppressive agents\r\n* Known hepatitis B or C infection \r\n* Congenital or acquired cellular and/or humoral immune deficiency\r\n* Other signs or symptoms of immune system suppression
Human immunodeficiency virus (HIV) infection without acquired immune deficiency syndrome (AIDS)-defining criteria are eligible
Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol
Human immunodeficiency virus (HIV) seropositivity or other congenital or acquired immune deficiency state, which would increase the risk of opportunistic infections and other complications during chemotherapy-induced lymphodepletion; if there is a positive result in the infectious disease testing that was not previously known, the patient will be referred to their primary physician and/or infectious disease specialist
History or evidence of melanoma associated with immunodeficiency states (eg, hereditary immune deficiency, organ transplant, or leukemia)
Patients with human immunodeficiency virus (HIV) who are not receiving cytochrome p450 inhibitors, and who have a minimum of 300+ CD4+ cells/mm^3, an undetectable viral load, and no history of acquired immune deficiency syndrome (AIDS) indicator conditions
Human immunodeficiency virus (HIV) seropositivity or other congenital or acquired immune deficiency state, which would increase the risk of opportunistic infections and other complications during chemotherapy-induced lymphodepletion; if there is a positive result in the infectious disease testing that was not previously known, the patient will be referred to their primary physician and/or infectious disease specialist
Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; note, HIV testing is required for entry into this protocol due to the immunologic basis for induction treatment.
Known immune deficiency, including human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus positive (HIV)(+) or has been diagnosed with acquired immune deficiency syndrome (AIDS)
Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition or known human immunodeficiency virus (HIV) seropositivity; note, however, that HIV testing is not required for entry into this protocol
Subjects with known infection with human immunodeficiency virus (HIV) or Acquired Immune Deficiency Syndrome (AIDS)
History of genetic or acquired immune suppression disease such as human immunodeficiency virus (HIV); subjects on immune suppressive therapy for organ transplant
Human immune deficiency virus
Subjects who require human immunodeficiency virus (HIV) protease inhibitors or those with acquired immune deficiency syndrome (AIDS)-related illness
Prior chronic immune suppressive state (acquired immune deficiency syndrome [AIDS], immunosuppressive therapy)
History of immune system abnormalities such as hyperimmunity (e.g., autoimmune diseases) that required systemic immunosuppression therapy and hypoimmunity (e.g., myelodysplastic disorders, marrow failures, acquired immunodeficiency syndrome (AIDS), ongoing pregnancy, transplant immunosuppression)
Known chronic infectious disease including, but not limited to, human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS)
Known acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition or other acquired or congenital disorder of the immune system
(2. continued) f) Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive. g) Active connective tissue disorders, such as lupus or scleroderma, that in the opinion of the treating physician may put the patient at high risk for radiation toxicity.
History of immune system abnormalities such as hyperimmunity (e.g., autoimmune diseases) and hypoimmunity (e.g., myelodysplastic disorders, marrow failures, acquired immune deficiency syndrome [AIDS], ongoing pregnancy, transplant immunosuppression)
For patients with human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS), the following must be true:\r\n* The patient is compliant on combination anti-retroviral therapy (CART)\r\n* The patient has cluster of differentiation (CD)4 count >= 200 at time of diagnosis
Serious uncontrolled infection; known human immunodeficiency virus (HIV)-seropositivity requiring retroviral therapy, or diagnosis of acquired immune deficiency syndrome (AIDS); diagnosis of chronic hepatitis B or C allowed
Conditions associated with increased susceptibility to infections with microorganisms; such conditions include, but are not limited to, acquired immune deficiency syndrome (AIDS), leukemia and intravenous (IV) drug abuse
Subjects with known infection with human immunodeficiency virus (HIV) or Acquired Immune Deficiency Syndrome (AIDS) (testing not required).
Human immunodeficiency virus (HIV)+/acquired immune deficiency syndrome (AIDS)
6. Subjects with known infection with human immunodeficiency virus or Acquired Immune Deficiency Syndrome (testing not required).
Has known human immunodeficiency virus or acquired immune deficiency syndrome, hepatitis B, hepatitis C, connective tissue disease, or other clinical diagnosis, ongoing or intercurrent illness that in the Investigators opinion should preclude the subject from participation;
History of immunosuppression, or conditions associated with congenital or acquired immune deficiency
Patients seropositive for the human immunodeficiency virus (HIV), and/or those who are taking anti-retroviral treatment for HIV/acquired immune deficiency syndrome (AIDS)
Patients with known history of human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS)
Known human immunodeficiency virus (HIV) positive or history of acquired immune deficiency syndrome (AIDS) or AIDS-defining illness
Active AIDS / HIV infection, clinically uncontrolled immune deficiency disorders;
Congenital or acquired immune deficiency at increased risk of infection.
Positive test for human immunodeficiency virus (HIV) 1&2 or known Acquired immune deficiency syndrome (AIDS)
Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol
Presence of human immunodeficiency virus (HIV) infection or acquired immune deficiency syndrome (AIDS)
Patients with acquired immune deficiency syndrome (AIDS) based upon current Center for Disease Control (CDC) definition or patients known to be human immunodeficiency virus (HIV) positive; note, however, that HIV testing is not required for entry into this protocol; the need to exclude these patients from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive
Co-morbidity with immunosuppressive disease such as acquired immune deficiency syndrome (AIDS)
Positive test result for human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS)
Immune deficiency diseases such as immunoglobulin deficiency or immunosuppressive therapy that might interfere with appropriate immune response
Individuals who are immunosuppressed by virtue of medication or disease, as determined by the examining study physician; this includes acquired immune deficiency syndrome (AIDS) patients and subjects taking oral steroids
History or serologic evidence of chronic viral infection (hepatitis B or C), human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS)
Known history of Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), hepatitis B or C.
Immune compromised individuals (human immunodeficiency virus [HIV], acquired immune deficiency syndrome [AIDS], immuno-suppressive drug therapy)
Patients with major chronic disease known to adversely affect PA, including human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS), congestive heart failure, tuberculosis
Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC (Centers for Disease Control) definition
Known history of HIV or AIDS
Active uncontrolled infection, including HIV/AIDS or Hepatitis B or C
Known HIV or AIDS-related illness
Known significant immunodeficiency due to underlying illness (e.g., HIV/AIDS) and/or immune-suppressive medication including high-dose corticosteroids
Known history of HIV or AIDS.
Known significant immunodeficiency due to underlying illness (e.g. HIV/AIDS) and/or immunosuppressive medication including high-dose corticosteroids.
Known HIV or AIDS-related illness
Active uncontrolled infection, including HIV/AIDS or Hepatitis B or C
Known infectious disease including HIV positivity or AIDS-related illness, HBV and HCV
Known HIV or AIDS
Known history of testing positive for HIV or AIDS
Has AIDS (HIV positive not excluded)
Known HIV positive or AIDS
Known HIV or AIDs-related illness.
HIV positive or an AIDS-related illness;
Known HIV positivity or AIDS-related illness
Known HIV or AIDs.
Known to be HIV positive or to have an AIDS-related illness.
Has known HIV or AIDS infection
Known HIV or AIDS
Known HIV or AIDS
Known HIV or AIDS
Known HIV or AIDS-related illness
Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness
Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness
Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, or known active or chronic hepatitis B or C infection
Known human immunodeficiency virus (HIV) positivity or acquired immunodeficiency syndrome (AIDS)-related illness
Active or known history (standard pre-ASCT assessments) of:\r\n* Hepatitis B or C infection\r\n* Human immunodeficiency virus (HIV)\r\n* Acquired immunodeficiency syndrome (AIDS)
Known history of human immunodeficiency virus (HIV) or acquired immunodeficiency-related (AIDS) illnesses.
Known human immunodeficiency virus or acquired immunodeficiency syndrome related illness.
Known positive test for hepatitis B, hepatitis C, human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS)
Individuals who are known to have acquired immunodeficiency syndrome (AIDS) (cluster of differentiation [CD] 4 < 200 or an AIDS-defining illness) or are known to be human immunodeficiency virus (HIV) positive and not on highly active antiretroviral therapy (HAART) are ineligible
HIV uninfected and infected women (without acquired immunodeficiency syndrome [AIDS] defining illness)
Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness that is not well controlled.
Known history of human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)
Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness (HIV-positive subjects on combination anti-retroviral therapy are ineligible
Acquired immune defects such as human immunodeficiency virus (HIV) or innate immunodeficiency
Active and clinically significant bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness (human immunodeficiency virus [HIV] testing is not required), including patients who have an active infection requiring systemic therapy
Known history of human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)
Known uncontrolled human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS); patients with documented controlled HIV infection (CD4 > 200 and undetectable viral load) will be included
Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, or hepatitis B or C
Human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)-related illness
Active and clinically significant bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness (HIV testing is not required)
Human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness
Known HIV or acquired immunodeficiency syndrome-related illness, acute or history of chronic hepatitis B or C.
Known significant immunodeficiency due to underlying illness (e.g. HIV/acquired immunodeficiency syndrome [AIDS]) and/or immune-suppressive medication including high-dose corticosteroids (defined as >= 20 mg/day prednisone or equivalent which is ongoing at the time of enrollment and/or was taken for more than 4 weeks within the preceding 2 months of enrollment)
Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness.
Current active infections with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), hepatitis B, and hepatitis C requiring treatment
Active bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) -related illness
Has a diagnosis of immunodeficiency, including human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)
Known active human immunodeficiency virus (HIV), acquired immunodeficiency syndrome (AIDS) related illness, or hepatitis B or C infection
Known severe congenital or acquired cellular or humoral immunodeficiency such as common variable immunodeficiency.
Active uncontrolled infection, including known history of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) or hepatitis B or C
Known history of human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)-related disease
Human immunodeficiency virus (HIV) virus infection irrespective of viral load, treatment status, or cluster of differentiation 4 (CD4) count, or acquired immunodeficiency syndrome (AIDS)-related illness; HIV testing is not required by this protocol
The subject has a history of human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), chronic hepatitis B or hepatitis C or is otherwise reasonably suspected to meet criteria for the diagnosis of a known congenital or acquired disorder causing systemic immunosuppression
Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness; (testing is not required for eligibility)
Significant immunodeficiency making the patient unlikely to benefit from pembrolizumab therapy including a diagnosis of acquired immunodeficiency syndrome (AIDS), active hepatitis B or hepatitis C, or organ transplant requiring immunosuppressive therapy
Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness
Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome-related disease
Other clinically significant disorders such as:\r\n* Known active infection requiring systemic treatment, infection with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, chronic hepatitis B or known or suspected active hepatitis C infection\r\n* Serious non-healing wound or ulcer\r\n* Malabsorption syndrome\r\n* Symptomatic hypothyroidism\r\n* Moderate to severe hepatic impairment (Child-Pugh B or C)\r\n* Requirement for hemodialysis or peritoneal dialysis\r\n* History of solid organ transplantation
Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness
Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness
Patients with known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness
Known human immunodeficiency virus- or acquired immunodeficiency syndrome-related illness.
Known human immunodeficiency virus (HIV) infection requiring antiretroviral medications and those with acquired immunodeficiency syndrome (AIDS)
Patients with known human immunodeficiency virus (HIV) positivity or acquired immunodeficiency syndrome (AIDS)-related illness are not eligible
Known history of human immunodeficiency virus (HIV) or acquired immunodeficiency-related (AIDS) illnesses.
Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, active or symptomatic viral hepatitis or chronic liver disease
The subject has a history of human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), chronic hepatitis B or hepatitis C or is otherwise reasonably suspected to meet criteria for the diagnosis of a known congenital or acquired disorder causing systemic immunosuppression
Patients with a known human immunodeficiency virus infection (HIV 1/2 antibodies) or acquired immunodeficiency syndrome (HIV/AIDS)
Active and clinically significant bacterial, fungal, or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS) related illness.
Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome((HIV/AIDS)
Have human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome-related illness.
Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness or other active infection; patients with HIV but no evidence of AIDS will be considered candidates
Known human immunodeficiency virus (HIV) positivity or autoimmune deficiency syndrome (AIDS)-related illness
Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness
If there is clinical suspicion of acquired immunodeficiency syndrome (AIDS), a human immunodeficiency virus (HIV) test is recommended within 42 days prior to registration; Note: HIV positive patients without AIDS are eligible for enrollment on this study
Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness
Known human immunodeficiency virus infection or acquired immunodeficiency syndrome-related illness.
Subject has a known active hepatitis B or C infection, Human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)
Participant has known human immunodeficiency virus infection or acquired immunodeficiency syndrome-related illness
History of human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)-related illness
Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness
Has human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)-related illness, or a history of immunodeficiency
Known human immunodeficiency virus (HIV) positivity or acquired immunodeficiency syndrome (AIDS) related illness or other serious medical illness
Has a known human immunodeficiency virus infection (HIV 1/2 antibodies) or acquired immunodeficiency syndrome (HIV/AIDS)
Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness
Known human immunodeficiency virus positivity or acquired immunodeficiency syndrome related illness or other serious medical condition
Patients with acquired immunodeficiency syndrome (AIDS-related illnesses) or known human immunodeficiency virus (HIV) disease must: Have a CD4 count greater than or equal to 200 cells/uL within 30 days prior to beginning study therapy; Be off all antiretroviral therapy (prophylaxis/treatment) greater than 60 days prior to beginning study therapy; Have no evidence of opportunistic infections.
Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness or other active infection
E 12. Acquired immunodeficiency syndrome (AIDS-related illnesses) or known HIV disease requiring antiretroviral treatment.
Active and clinically significant bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness.
Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness
Known human immunodeficiency virus (HIV) positivity or acquired immune deficiency syndrome (AIDS)-related illness, active hepatitis B virus, or active hepatitis C virus
Evidence of ongoing systemic bacterial, fungal, or viral infection. Known human immunodeficiency virus (HIV) infection or acquired-immunodeficiency syndrome (AIDS)-related illness
Acquired immunodeficiency syndrome (AIDS)-related illnesses or known Human immunodeficiency virus (HIV) disease requiring antiretroviral treatment.
Acquired immuno deficiency syndrome (AIDS-related illnesses) or known human immunodeficiency virus (HIV) disease requiring antiretroviral treatment
Known human immunodeficiency virus-positive serology, acquired immunodeficiency syndrome (AIDS), or an AIDS-related illness.
Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness, which may compromise the efficacy of immunostimulatory therapy
Human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS)
Human immunodeficiency virus infection or acquired immunodeficiency syndrome-related illness.
Known seropositivity for human immunodeficiency virus (HIV) or diagnosis of acquired immunodeficiency syndrome (AIDS), positive for hepatitis B surface antigen, or seropositive for hepatitis C virus
Human immunodeficiency virus or acquired immunodeficiency syndrome
Coexisting cancer in other organs or acquired immunodeficiency syndrome/human immunodeficiency virus (AIDS/HIV)
Has been diagnosis of active acquired immunodeficiency syndrome (AIDS) or hepatitis B/C and other significant disease or disorders
Active and clinically significant bacterial, fungal, or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness
Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness